Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients

• Status: Recruiting
• Trial end date: 2021-11-23
• Target enrollment: 0
• Participant gender: All

Summary

Aceruloplasminemia is an autosomal recessive disorder characterized by iron deposition in the brain and visceral organs. Deferiprone was used to treat aceruloplasminemia in previous study. In this study, we will assess the clinical curative effect evaluation of oral deferiprone in Chinese aceruloplasminemia patients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital of Fujian Medical University
• Treatments: Deferiprone

Criteria

Inclusion Criteria:

• Age 18-80 years

• Diagnosed with aceruloplasminaemia

• Genetically confirmed diagnosis of aceruloplasminaemia

Exclusion Criteria:

• Contraindications to deferiprone therapy

• Pregnancy was excluded in women of childbearing age